outcomes
Our forward-focused conversation continues with this third installment in a series focused on Advancing Continuing Medical Education (CME*). Most recently, our article focused on team-based education and the importance of design.
By: Sarah Nisly, PharmD, MEd, BCPS, FCCP; Caroline Pardo, PhD, CHCP, FACEHP; Cody Ortmann
outcomes
This is the second article in a series, focused on original research that was first presented at the Alliance 2023 Industry Summit (AIS) session, “What’s next? Revisiting ‘20 Predictions for the Future of CPD’: Looking...
By: Caroline Pardo, PhD, CHCP, FACEHP; Sarah Nisly, PharmD, MEd, BCPS, FCCP; Dustin Ensign, CHCP
outcomes
A recent claim about natural language processing (NLP) techniques caught my attention. An Almanac ChatGPT-generated article suggested that “ChatGPT can make sense of vast amounts of qualitative data received from interviews and open-ended...
By: Alexandra Howson, PhD, CHCP
outcomes
In late 2020, something big happened in interventional cardiology: the FDA approved intravascular lithotripsy (IVL) to treat coronary lesions1. IVL balloon technology has been used to dilate lesions, including calcified lesions, in the peripheral...
outcomes
Over the past decade, continuing medical education (CME*) has undergone transformations driven by the evolving needs of healthcare providers. In 2012, Dr. Curtis Olson, as the editor in chief of JCEHP, outlined a collection of evolving themes and...
By: Sarah A. Nisly, PharmD, MEd, BCPS, FCCP; Caroline O. Pardo, PhD, CHCP, FACEHP; Wendy Cerenzia, MS; Emily Belcher
outcomes
While the rapidly evolving field of immuno-oncology (I-O) has precipitated unprecedented advancements in cancer treatment, there are significant clinical gaps related to I-O biomarker testing and patient care.
By: Melissa Kelly, PhD; Joseph Kim, MD, MPH, MBA, FACEHP, CPHQ; and Kellie Beumer
outcomes
For decades, breast cancer has been classified as HER2 positive or HER2 negative. However, in 2019, research began to emerge showing promising results in breast cancers with low levels of HER2, for which there were no approved therapies.
By: Kellie Beumer; Melissa Kelly, PhD; Joseph Kim, MD, MPH, MBA, FACEHP, CPHQ; Jim Mortimer; and Kevin Obholz, PhD
outcomes
The opioid crisis continues to plague the U.S., impacting communities across the country. Numerous educational initiatives have been developed and distributed to help clinicians tackle this challenge, with several programs emphasizing the...
By: Kenny Cox, Brett Gordeau, John Kriak, Michelle Skidmore, Marlene Heeg
outcomes
We outline uses for data, big and small, while also calling all CPD/CME members to rethink the use of data to drive decisions and change for patients.
By: Sarah A. Nisly, PharmD, MEd, BCPS, FCCP; and Caroline O. Pardo, PhD, CHCP, FACEhp